BNTX vs. PFE

Last updated Jun 4, 2026

BNTX (BioNTech SE) and PFE (Pfizer Inc.) are both stocks. Both are in the Healthcare sector — BNTX in Biotechnology, PFE in Drug Manufacturers - General. Over the past 5 years, BNTX returned -17.26%/yr vs -3.51%/yr for PFE. At a 0.35 correlation, their price movements are largely independent.

Performance

BNTX vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioNTech SE (BNTX) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BNTX achieves a -7.09% return, which is significantly lower than PFE's 5.18% return.

BNTX

• 1D: -0.77%
• 1M: -10.97%
• YTD: -7.09%
• 6M: -8.56%
• 1Y: -23.51%
• 3Y*: -6.48%
• 5Y*: -17.26%
• 10Y*: —

PFE

• 1D: -0.82%
• 1M: -2.06%
• YTD: 5.18%
• 6M: 2.42%
• 1Y: 16.11%
• 3Y*: -7.32%
• 5Y*: -3.51%
• 10Y*: 1.85%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BNTX vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BNTX BioNTech SE	-7.09%	-16.45%	7.97%	-29.74%	-40.40%	216.24%	140.61%	137.92%
PFE Pfizer Inc.	5.18%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	10.53%

Correlation

The correlation between BNTX and PFE is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.31
Correlation (3Y) Calculated over the trailing 3-year period	0.41
Correlation (5Y) Calculated over the trailing 5-year period	0.40
Correlation (All Time) Calculated using the full available price history since Oct 11, 2019	0.35

The correlation between BNTX and PFE shifts across timeframes, from 0.31 (1 year) to 0.41 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap BNTX : $22.37B PFE : $145.22B
EPS BNTX : -$5.14 PFE : $1.31
PS Ratio BNTX : 7.73 PFE : 2.28
PB Ratio BNTX : 1.20 PFE : 1.61
Total Revenue (TTM) BNTX : $2.80B PFE : $63.32B
Gross Profit (TTM) BNTX : $2.05B PFE : $43.91B
EBITDA (TTM) BNTX : -$815.04M PFE : $16.94B

Return for Risk

BNTX vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTX

BNTX Risk / Return Rank: 13
BNTX Sharpe Ratio Rank: 16
BNTX Sortino Ratio Rank: 18
BNTX Omega Ratio Rank: 16
BNTX Calmar Ratio Rank: 11
BNTX Martin Ratio Rank: 3

PFE

PFE Risk / Return Rank: 61
PFE Sharpe Ratio Rank: 62
PFE Sortino Ratio Rank: 57
PFE Omega Ratio Rank: 55
PFE Calmar Ratio Rank: 67
PFE Martin Ratio Rank: 65

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTX vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioNTech SE (BNTX) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNTX	PFE	Difference
Sharpe ratio Return per unit of total volatility	-0.58	0.68	-1.25
Sortino ratio Return per unit of downside risk	-0.58	1.18	-1.76
Omega ratio Gain probability vs. loss probability	0.92	1.14	-0.22
Calmar ratio Return relative to maximum drawdown	-0.79	1.41	-2.20
Martin ratio Return relative to average drawdown	-1.68	2.91	-4.59
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNTX vs. PFE - Sharpe Ratio Comparison

The current BNTX Sharpe Ratio is -0.58, which is lower than the PFE Sharpe Ratio of 0.68. The chart below compares the historical Sharpe Ratios of BNTX and PFE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BNTX	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.58	0.68	-1.25
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.31	-0.14	-0.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.08	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.42	0.23	+0.19

Drawdowns

BNTX vs. PFE - Drawdown Comparison

The maximum BNTX drawdown since its inception was -82.08%, which is greater than PFE's maximum drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for BNTX and PFE.

Drawdown Indicators

	BNTX	PFE	Difference
Max Drawdown Largest peak-to-trough decline	-82.08%	-58.96%	-23.12%
Max Drawdown (1Y) Largest decline over 1 year	-29.71%	-11.47%	-18.24%
Max Drawdown (3Y) Largest decline over 3 years	-37.35%	-40.75%	+3.40%
Max Drawdown (5Y) Largest decline over 5 years	-82.08%	-58.96%	-23.12%
Max Drawdown (10Y) Largest decline over 10 years	—	-58.96%	—
Current Drawdown Current decline from peak	-79.77%	-47.49%	-32.28%
Average Drawdown Average peak-to-trough decline	-56.12%	-17.68%	-38.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.30%	5.54%	+8.76%

Volatility

BNTX vs. PFE - Volatility Comparison

BioNTech SE (BNTX) has a higher volatility of 8.96% compared to Pfizer Inc. (PFE) at 4.07%. This indicates that BNTX's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNTX	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.96%	4.07%	+4.89%
Volatility (6M) Calculated over the trailing 6-month period	33.77%	14.64%	+19.13%
Volatility (1Y) Calculated over the trailing 1-year period	41.08%	23.85%	+17.23%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.62%	25.49%	+30.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.31%	23.88%	+52.43%

Dividends

BNTX vs. PFE - Dividend Comparison

BNTX has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.79%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BNTX BioNTech SE	0.00%	0.00%	0.00%	0.00%	2.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer Inc.	6.79%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Financials

Frequently Asked Questions

Can I hold both BNTX and PFE in my portfolio?

BNTX and PFE have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BNTX or PFE?

BNTX has higher volatility (8.96%) compared to PFE (4.07%). In terms of maximum drawdown, BNTX dropped -82.08% vs PFE's -58.96%.

Which has better risk-adjusted returns?

PFE currently has the higher Sharpe Ratio (0.68 vs -0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.